Analytical Data
-
基因名
c-MPL/Thrombopoietin R
- Application
-
种属
Canine
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_038543911
-
表达区间
Q22-W489
-
蛋白长度
Partial
-
分子量
65-75 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
c-MPL (the receptor for thrombopoietin) plays a crucial role in thrombopoiesis, the process of platelet production in the bone marrow. Thrombopoietin (TPO), a key regulator of this process, binds to c-MPL, initiating signaling pathways that promote the survival, proliferation, and differentiation of megakaryocytes, the progenitor cells for platelets. Dysfunctional c-MPL signaling is implicated in various hematological disorders, including immune thrombocytopenic purpura (ITP) and certain myeloproliferative neoplasms. As a result, research into c-MPL and TPO has gained significant attention, particularly in the development of therapeutic strategies aimed at modulating platelet production. Recombinant c-MPL/TPO receptor proteins are being studied for their potential to enhance platelet counts in patients with thrombocytopenia, enhance understanding of c-MPL signaling pathways, and explore novel treatment paradigms. These proteins serve not only as tools for basic research in hematology but also hold promise in clinical applications, including the design of new therapies for platelet disorders and the improvement of outcomes in patients undergoing chemotherapy or suffering from other conditions that lead to reduced platelet levels. The ongoing exploration of c-MPL/TPO interactions may lead to innovative approaches for managing bleeding disorders and improving the quality of life for affected patients.
